ANIKHealthcare · Drug Manufacturers - Specialty & GenericThe 2 Wall Street analysts covering Anika Therapeutics, Inc. hold a median 12-month price target of $21 — -4.7% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 100 of 100 as at 12 Aug 2026 — among the strongest tenth. The factors read stronger than the Street's target implies. That gap is the story on this page.
Consensus tells you what everyone already believes. The model scores Anika Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Revisions (95): Analysts have, on balance, been raising their forecasts.
Accruals (60): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on ANIK, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits −4.7% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 30 July 2026 | B. Riley Securities | Maintains | Buy | $18 → $21 |
| 27 Feb 2026 | Barrington Research | Maintains | Outperform | $16 → $17 |
| 27 Feb 2026 | Barrington Research | Maintains | Outperform | — |
| 9 Jan 2026 | Barrington Research | Maintains | Outperform | — |
| 6 Nov 2025 | Barrington Research | Maintains | Outperform | — |
| 23 Sept 2025 | Barrington Research | Maintains | Outperform | — |
| 31 July 2025 | Barrington Research | Maintains | Outperform | — |
| 12 May 2025 | Barrington Research | Maintains | Outperform | — |
| 13 Mar 2025 | Barrington Research | Maintains | Outperform | — |
| 1 Nov 2024 | Barrington Research | Maintains | Outperform | — |
| 22 Oct 2024 | Barrington Research | Maintains | Outperform | — |
| 9 Aug 2024 | Barrington Research | Maintains | Outperform | — |
| 29 May 2024 | Stephens & Co. | Reiterates | Equal-Weight | — |
| 9 May 2024 | Barrington Research | Maintains | Outperform | — |
| 14 Mar 2024 | Barrington Research | Maintains | Outperform | — |
| 14 Mar 2024 | Stephens & Co. | Reiterates | Equal-Weight | — |
| 3 Jan 2024 | Barrington Research | Maintains | Outperform | — |
| 3 Nov 2023 | Barrington Research | Maintains | Outperform | — |
| 14 Aug 2023 | Barrington Research | Upgrade | Outperform | — |
| 10 Aug 2023 | Stephens & Co. | Maintains | Equal-Weight | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. ANIK appears on the weeks it earns a place.
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 97% of US stocks
Cheaper than 48% of US stocks
Cheaper than 44% of US stocks
Cheaper than 2% of US stocks
Higher than 64% of US stocks
Higher than 54% of US stocks
Higher than 79% of US stocks
Higher than 66% of US stocks
Higher than 26% of US stocks
Higher than 42% of US stocks
Higher than 40% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Anika Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Zacks Investment Research highlighted five stocks, including Anika Therapeutics (ANIK), that have demonstrated strong recent price gains and earnings growth as markets rally during the August period.
Why it matters — ANIK being named among stocks with notable price strength and earnings growth signals favorable recent market momentum for the company.
Zacks reported that Anika Therapeutics (ANIK) passed its shorter-term trading strategy-based screen, which identifies fundamentally sound stocks with recent price trends. The report suggests Anika could be a solid choice for shorter-term investors looking to capitalize on this trend.
Why it matters — This highlights that Anika's recent price trend has drawn attention from a Zacks trading-screen strategy, which ANIK watchers would follow as a signal on the stock's near-term movement.
Seeking Alpha published a transcript of Anika Therapeutics' Q2 2026 earnings call, summarizing management's discussion of the company's financial results and business performance for the quarter.
Why it matters — ANIK investors and analysts review earnings call transcripts for management commentary on operational trends, financial health, and strategic direction beyond what financial statements alone reveal.
Anika Therapeutics reported higher second-quarter revenue, expanded gross margin, and its strongest adjusted EBITDA performance since 2020, driven by international commercial growth and manufacturing improvements.
Why it matters — The results signal that Anika's profitability is improving, which would be a key concern for investors monitoring the company's financial turnaround.
The 2 Wall Street analysts covering Anika Therapeutics, Inc. have a median 12-month price target of $21, with estimates ranging from $21 to $21. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 2 analysts covering Anika Therapeutics, Inc., 2 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Anika Therapeutics, Inc. 100 out of 100 across roughly 4,600 US stocks as at 12 Aug 2026. None of this is personal advice — it does not consider your circumstances.
As at 12 Aug 2026, Anika Therapeutics, Inc. ranks 100 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Revisions (95 of 100).
No one can know that. What the data says: the median 12-month target from 2 analysts implies -4.7% from the last close, and Ticker Nerd's factor model ranks Anika Therapeutics, Inc. 100 out of 100 as at 12 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Anika Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ANIK are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $21 to $21 over the next 12 months.
Anika Therapeutics, Inc. returned +152.6% over the 12 months to 12 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
Anika Therapeutics Inc. is a joint preservation company specializing in the design, development, manufacturing, and commercialization of hyaluronic acid (HA)-based innovations for orthopedic care.
The most recent item we track (Zacks Investment Research, 10 Aug 2026): "5 Stocks With Recent Price Strength to Tap August Rally". Zacks Investment Research highlighted five stocks, including Anika Therapeutics (ANIK), that have demonstrated strong recent price gains and earnings growth as markets rally during the August period.
Anika Therapeutics Inc. is a joint preservation company specializing in the design, development, manufacturing, and commercialization of hyaluronic acid (HA)-based innovations for orthopedic care. It focuses on early intervention solutions in osteoarthritis pain management, regenerative medicine, sports medicine, and bone-preserving joint solutions, delivered through products like Orthovisc, Monovisc, and Cingal for viscosupplementation injections that provide pain relief and restore joint function. The company also offers regenerative products such as Hyalofast and Tactoset for tissue repair, alongside non-orthopedic offerings including veterinary products like Hyvisc for equine joint issues, anti-adhesion barriers like Hyalobarrier for surgical use, and ophthalmic solutions. Anika Therapeutics Inc. partners with clinicians and distributes its portfolio globally to surgeons, hospitals, and ambulatory surgery centers, emphasizing minimally invasive treatments that delay invasive procedures and promote active living. Founded in 1992 and headquartered in Bedford, Massachusetts, it holds a leading position in HA-based osteoarthritis pain management in the U.S. market.
CEO Dr. Cheryl Renee Blanchard Ph.D. · 288 employees · United States · https://www.anika.com